372 related articles for article (PubMed ID: 31985914)
1. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
2. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
[TBL] [Abstract][Full Text] [Related]
4. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
[TBL] [Abstract][Full Text] [Related]
5. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
Stein Gold L; Pariser DM; Guenin E
J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
[TBL] [Abstract][Full Text] [Related]
6. New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
Eichenfield LF; Tanghetti EA; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jun; 19(6):602-610. PubMed ID: 32574011
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC; Baldwin H; Stein Gold L; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
[TBL] [Abstract][Full Text] [Related]
8. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
Lain E; Day D; Harper J; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1128-1138. PubMed ID: 31741356
[TBL] [Abstract][Full Text] [Related]
9. Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.
Kircik LH; Gold LS; Beer K; Tan J; Baldwin H; Guenin E; Kang R; Varughese J
J Drugs Dermatol; 2020 Aug; 19(8):777-783. PubMed ID: 32845584
[TBL] [Abstract][Full Text] [Related]
10. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
[TBL] [Abstract][Full Text] [Related]
11. Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.
Bhatia N; Weiss JS; Sadick N; Cook-Bolden FE; Tyring SK; Guenin E; Loncaric A; Harris S
J Drugs Dermatol; 2020 Jul; 19(7):727-734. PubMed ID: 32726105
[TBL] [Abstract][Full Text] [Related]
12. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
Han G; Armstrong AW; Desai SR; Guenin E
J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
[TBL] [Abstract][Full Text] [Related]
14. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
15. Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.
Stein Gold L; Kircik L; Baldwin H; Callender V; Tanghetti E; Del Rosso J; Zeichner J; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Jun; 21(6):587-595. PubMed ID: 35674760
[TBL] [Abstract][Full Text] [Related]
16. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
Green LJ; Del Rosso JQ; Tanghetti EA; Guenin E
J Drugs Dermatol; 2021 Jun; 20(6):608-615. PubMed ID: 34076400
[TBL] [Abstract][Full Text] [Related]
17. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
19. Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.
Kircik LH; Lain E; Gold M; Katz B; Baldwin H; Guenin E; Loncaric A; Pillai R
J Drugs Dermatol; 2020 Nov; 19(11):1086-1092. PubMed ID: 33196747
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
